DK2211846T3 - Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser - Google Patents

Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser

Info

Publication number
DK2211846T3
DK2211846T3 DK08854467.1T DK08854467T DK2211846T3 DK 2211846 T3 DK2211846 T3 DK 2211846T3 DK 08854467 T DK08854467 T DK 08854467T DK 2211846 T3 DK2211846 T3 DK 2211846T3
Authority
DK
Denmark
Prior art keywords
cmt
approaches
treatment
related disorders
hitherto unknown
Prior art date
Application number
DK08854467.1T
Other languages
English (en)
Inventor
Daniel Cohen
Ilya Chumakov
Oxana Guerassimenko
Serguei Nabirochkin
Original Assignee
Pharnext
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharnext filed Critical Pharnext
Application granted granted Critical
Publication of DK2211846T3 publication Critical patent/DK2211846T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
DK08854467.1T 2007-11-30 2008-11-28 Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser DK2211846T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07301614A EP2065038A1 (en) 2007-11-30 2007-11-30 New therapeutic approaches for treating Charcot-Marie-Tooth disease
US99180007P 2007-12-03 2007-12-03
PCT/EP2008/066468 WO2009068668A1 (en) 2007-11-30 2008-11-28 New therapeutic approaches for treating cmt and related disorders

Publications (1)

Publication Number Publication Date
DK2211846T3 true DK2211846T3 (da) 2013-04-29

Family

ID=39264515

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12196650.1T DK2609916T3 (da) 2007-11-30 2008-11-28 Nye terapeutiske tilgange til behandling af CMT og relaterede lidelser
DK08854467.1T DK2211846T3 (da) 2007-11-30 2008-11-28 Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK12196650.1T DK2609916T3 (da) 2007-11-30 2008-11-28 Nye terapeutiske tilgange til behandling af CMT og relaterede lidelser

Country Status (24)

Country Link
US (6) US8992891B2 (da)
EP (4) EP2065038A1 (da)
JP (4) JP5953000B2 (da)
KR (1) KR101546031B1 (da)
CN (2) CN104257657B (da)
AU (1) AU2008328745B2 (da)
BR (1) BRPI0819678A2 (da)
CA (3) CA3031490C (da)
CY (2) CY1113980T1 (da)
DK (2) DK2609916T3 (da)
EA (3) EA019402B1 (da)
ES (3) ES2703508T3 (da)
HR (2) HRP20130345T1 (da)
HU (1) HUE040596T2 (da)
IL (1) IL205741A0 (da)
LT (1) LT2609916T (da)
MX (1) MX2010005709A (da)
NZ (1) NZ585440A (da)
PL (2) PL2211846T3 (da)
PT (2) PT2609916T (da)
SI (2) SI2609916T1 (da)
TR (1) TR201819564T4 (da)
WO (1) WO2009068668A1 (da)
ZA (1) ZA201003610B (da)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US20110213193A1 (en) * 2008-08-28 2011-09-01 The Florida International University Board Of Trustees Magnetic Nanodelivery of Therapeutic Agents Across the Blood Brain Barrier
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
ES2532006T3 (es) * 2009-11-20 2015-03-23 Pharnext Nuevas herramientas de diagnóstico para la enfermedad de Charcot-Marie-Tooth
HUE034866T2 (hu) * 2010-01-15 2018-03-28 Inst Nat Sante Rech Med NKCC inhibitorok az autizmus kezelésére
AU2011311531B2 (en) * 2010-10-08 2014-11-20 Life Sciences Research Partners Vzw HDAC inhibitors to treat Charcot-Marie-Tooth disease
CN102464610B (zh) * 2010-11-16 2014-07-30 北大方正集团有限公司 一种美替拉酮的制备方法
US9592288B2 (en) 2011-02-18 2017-03-14 The Scripps Research Institute Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
ES2702848T3 (es) 2011-02-23 2019-03-05 Coeruleus Ltd Complejos de flumazenil, composiciones que los comprenden y usos de los mismos
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (en) 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
CN102247324B (zh) * 2011-07-14 2012-11-21 海南美兰史克制药有限公司 一种氟马西尼脂质体注射液
CN102887830B (zh) * 2012-09-04 2013-11-27 苏州弘森药业有限公司 一种盐酸酚苄明的制备方法
US10016142B2 (en) 2012-10-19 2018-07-10 Sidewaystrategies Llc Systems and methods for nerve mapping and monitoring
US20150329483A1 (en) * 2012-12-17 2015-11-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and Pharmaceutical Compositions for the Treatment of X-Linked Charcot-Marie-Tooth
NZ714684A (en) 2013-06-05 2020-05-29 Pharnext Stable oral solutions for combined api
WO2015121218A1 (en) 2014-02-11 2015-08-20 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
UA118785C2 (uk) * 2014-02-24 2019-03-11 Фарнекст Композиції для лікування механічних пошкоджень нервів
US20160339015A1 (en) * 2015-05-20 2016-11-24 Lupin Inc. Oral pharmaceutical composition of methylergonovine
WO2017156242A1 (en) * 2016-03-09 2017-09-14 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting pmp22 expression
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US11272871B2 (en) 2016-07-14 2022-03-15 Sidewaystrategies Llc System and methods for improving diagnostic evoked potential studies for functional assessments of nerves and nerve pathways
CA3044691A1 (en) * 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
BR112020001755A2 (pt) 2017-07-28 2020-07-21 Applied Therapeutics Inc. composições e métodos para o tratamento de galactosemia
CA3136100A1 (en) * 2019-05-07 2020-11-12 Stephan L. ZUCHNER Treatment and detection of inherited neuropathies and associated disorders
CA3176768A1 (en) * 2020-05-01 2021-11-04 Shoshana SHENDELMAN Aldose reductase inhibitors for treating sorbitol dehydrogenase deficiency
EP4019016A1 (en) * 2020-12-24 2022-06-29 Allaysis, LLC Methods of administering intravenous baclofen
US11523984B1 (en) * 2021-11-12 2022-12-13 Amneal Pharmaceuticals Llc Compositions and methods of administering baclofen
WO2023182288A1 (ja) * 2022-03-22 2023-09-28 国立大学法人京都大学 シャルコー・マリー・ツース病の治療または予防薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW427904B (en) 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
RU2184570C2 (ru) 1997-09-30 2002-07-10 Дайити Фармасьютикал Ко., Лтд. Препараты для орального введения
WO2000017358A2 (en) * 1998-09-22 2000-03-30 Incyte Genomics, Inc. Human chaperone proteins
EP1117425A2 (en) * 1998-10-02 2001-07-25 Celtrix Pharmaceuticals, Inc. Methods for the treatment of non-thyroid disorders
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
WO2002049607A2 (en) 2000-12-20 2002-06-27 Firmenich Sa Flavoured oral drug delivery system
JP3805646B2 (ja) 2001-05-25 2006-08-02 久光メディカル株式会社 医薬液剤
CN1520286B (zh) * 2001-07-04 2010-12-01 太阳医药工业有限公司 胃滞留控制药物释出系统
IL163911A0 (en) * 2002-03-14 2005-12-18 Euro Celtique Sa Naltrexone hydrochloride compositions
DK1578350T3 (da) * 2002-03-26 2009-08-10 Euro Celtique Sa Sammensætninger med gel-coating med depotvirkning
FR2842422B1 (fr) 2002-07-16 2006-06-30 Univ Aix Marseille Ii Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
JP2004049093A (ja) * 2002-07-18 2004-02-19 Meiji Milk Prod Co Ltd 腸内酪酸上昇食品組成物および医薬品
WO2004019938A1 (en) 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
RU2224518C1 (ru) * 2003-02-10 2004-02-27 Дулькис Мария Дмитриевна Жидкая лекарственная форма налтрексона
CA2516816C (en) * 2003-02-24 2012-02-07 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
PT2368553E (pt) * 2003-04-08 2015-03-03 Progenics Pharm Inc Formulações farmacêuticas contendo metilnaltrexona
EP1613324A2 (en) * 2003-04-14 2006-01-11 Pain Therapeutics, Inc. Methods for the treatment of pain comprising opioid antagonists
WO2004103263A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
AU2004277898B2 (en) 2003-09-25 2009-04-02 Euro-Celtique S.A. Pharmaceutical combinations of hydrocodone and naltrexone
WO2005053612A2 (en) 2003-11-26 2005-06-16 Shire Laboratories, Inc. Micellar systems useful for delivery of lipophilic or hydrophobic compounds
FR2865648B1 (fr) * 2004-02-03 2006-06-30 Philippe Perovitch Procede de diffusion de molecules insolubles en milieu aqueux et composition mettant en oeuvre ce procede
US20050220863A1 (en) 2004-04-02 2005-10-06 Chien-Hsuan Han Pharmaceutical dosage forms having controlled release properties that contain a GABAB receptor agonist
JP2006131545A (ja) 2004-11-05 2006-05-25 Japan Science & Technology Agency 神経因性疼痛治療剤
GB0509052D0 (en) * 2005-05-04 2005-06-08 Aimsco Ltd Combination therapy
US20070099947A1 (en) 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
DE102006016990A1 (de) * 2006-04-11 2007-10-18 Hermann, Holger Lars, Dr. Verwendung von Baclofen und Baclofen-Derivaten zur Entzugs- und/oder Substitutionsbehandlung bei Abhängigkeit von GHB und/oder GHB-Analogen
EP2377531A2 (en) * 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2026813A2 (en) * 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2008086492A1 (en) 2007-01-11 2008-07-17 Xenoport, Inc. Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment
US20080255062A1 (en) 2007-02-13 2008-10-16 University Of Manitoba Axon regeneration from adult sensory neurons
US7806721B2 (en) * 2007-08-02 2010-10-05 Tyco Electronics Corporation Patch panel modular jack assembly
EP2065038A1 (en) 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en) * 2008-06-18 2009-12-23 Pharnext Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
EP2263665A1 (en) 2009-06-02 2010-12-22 Pharnext New compositions for treating CMT and related disorders
US9393241B2 (en) 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2322163A1 (en) 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
IT1400067B1 (it) 2010-05-21 2013-05-17 Molteni & C Spray nasale liquido contenente naltrexone a bassi dosaggi.
EP2560631B1 (en) 2011-03-01 2014-01-15 Pharnext Baclofen and acamprosate based therapy of neurogical disorders
US9931326B2 (en) 2011-03-29 2018-04-03 Pharnext Composition comprising torasemide and baclofen for treating neurological disorders
NZ714684A (en) 2013-06-05 2020-05-29 Pharnext Stable oral solutions for combined api
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease

Also Published As

Publication number Publication date
US20100310641A1 (en) 2010-12-09
US20180360785A1 (en) 2018-12-20
PT2211846E (pt) 2013-05-10
EA019402B1 (ru) 2014-03-31
PL2609916T3 (pl) 2019-03-29
HUE040596T2 (hu) 2019-03-28
AU2008328745A1 (en) 2009-06-04
EA035711B1 (ru) 2020-07-29
HRP20130345T1 (hr) 2013-07-31
EA201301078A1 (ru) 2014-06-30
US20180250289A1 (en) 2018-09-06
CA3031490A1 (en) 2009-06-04
ES2831855T3 (es) 2021-06-09
MX2010005709A (es) 2010-11-05
CN101883561B (zh) 2014-07-30
CY1113980T1 (el) 2016-07-27
CA3031490C (en) 2021-05-04
BRPI0819678A2 (pt) 2017-05-09
CY1121183T1 (el) 2020-05-29
JP2019142917A (ja) 2019-08-29
US20180338969A1 (en) 2018-11-29
EP3459535A1 (en) 2019-03-27
HRP20182147T8 (hr) 2019-04-19
EP2065038A1 (en) 2009-06-03
EP2609916B1 (en) 2018-11-07
CA2705408C (en) 2019-04-23
US10322101B2 (en) 2019-06-18
ZA201003610B (en) 2011-06-29
PL2211846T3 (pl) 2013-09-30
SI2609916T1 (sl) 2019-03-29
EP3459535B1 (en) 2020-08-12
US10441558B2 (en) 2019-10-15
US10463640B2 (en) 2019-11-05
EA201791669A3 (ru) 2018-03-30
CA3031484C (en) 2021-05-04
CN104257657B (zh) 2017-07-04
CA2705408A1 (en) 2009-06-04
NZ585440A (en) 2011-12-22
JP2018109043A (ja) 2018-07-12
EP2211846B1 (en) 2013-02-27
US20200155491A1 (en) 2020-05-21
ES2703508T3 (es) 2019-03-11
KR101546031B1 (ko) 2015-08-25
CA3031484A1 (en) 2009-06-04
EA032767B1 (ru) 2019-07-31
JP5953000B2 (ja) 2016-07-13
KR20100088160A (ko) 2010-08-06
US20150157626A1 (en) 2015-06-11
TR201819564T4 (tr) 2019-01-21
JP6608309B2 (ja) 2019-11-20
AU2008328745B2 (en) 2014-01-30
IL205741A0 (en) 2010-11-30
JP2011504915A (ja) 2011-02-17
LT2609916T (lt) 2019-02-11
US8992891B2 (en) 2015-03-31
CN101883561A (zh) 2010-11-10
PT2609916T (pt) 2019-01-10
CN104257657A (zh) 2015-01-07
JP2016145227A (ja) 2016-08-12
ES2408785T3 (es) 2013-06-21
EP2211846A1 (en) 2010-08-04
HRP20182147T1 (hr) 2019-03-08
EA201000914A1 (ru) 2010-12-30
WO2009068668A1 (en) 2009-06-04
EP2609916A1 (en) 2013-07-03
DK2609916T3 (da) 2019-01-21
EA201791669A2 (ru) 2017-12-29
SI2211846T1 (sl) 2013-07-31

Similar Documents

Publication Publication Date Title
DK2211846T3 (da) Hidtil ukendte tilgange til behandling af CMT- og beslÇgtede lidelser
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
BR112012001325A2 (pt) tratamento de distúrbios do fígado com inibidaores de pi3k
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2451796T3 (da) Tofaanaloger til behandling af dermatologiske lidelser eller tilstande
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
DK2240130T3 (da) Indretning til behandling af fedme
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK2794604T3 (da) Hidtil ukendte dihydropyrimidinoisoquinolinoner og farmaceutiske sammensætninger deraf til behandlingen af inflammatoriske lidelse
DK2445912T3 (da) Ny forbindelse anvendelig til behandlingen af degenerative og inflammatoriske sygdomme
BRPI0813516A2 (pt) Tratamento de distúrbios proliferativos de células b
DK2111555T3 (da) Diagnosticering af præeklampsi
BRPI0816789A2 (pt) Goji e inflamação
DK2235002T3 (da) 4-pyridinonforbindelser og anvendelse heraf til behandling af cancer
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
DK2164572T3 (da) Carbamoyl-cyclohexaner til behandling af akut mani
DK2478905T3 (da) Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler
DK2501381T3 (da) Behandling af atrieflimmer
DK2175849T3 (da) Behandling af melanomer
DK3106166T3 (da) Forbindelser til behandling af smertesyndrom og andre lidelser
BRPI0821026A2 (pt) Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
DK2173366T3 (da) Anvendelse af bigift til behandling af parkinson's sygdom